PolyPid (PYPD) Q3 2026 earnings review
PolyPid collected $30 million from its partner, but spending rose
PolyPid, which develops a slow-release antibiotic for bowel surgery, kept to its regulatory timetable while its spending climbed. It filed for approval in Europe on schedule and regained its European sales rights. Excluding a one-off accounting gain, its quarterly loss widened to $8.3 million, by our math.
| Net loss, excluding a one-off gain | $8.3M +11% from a year ago; reported loss $5.8M |
|---|---|
| Research and development spending | $6.5M +24% from a year ago |
| Cash and deposits at September 30 | $15.5M plus $15M from Azurity received after the quarter |
| Funding outlook | Unchanged cash to last into 2028 |
⚖️ Verdict: 🟢 Bullish
The story got better because PolyPid met its European filing date and collected the full payment from Azurity, its US partner. One caution: by our math, its cash now covers less than four quarters of spending at this pace. Its plan to fund the business into 2028 rests on payments tied to approval and sales.
The question now is whether Azurity can get hospitals to use the drug before PolyPid's cash runs low. If approval comes on time and hospitals adopt the drug quickly, partner payments fund the company; if not, it may have to sell shares. The FDA decision due November 28 will tell first.
🐂 Bull Case
FDA Review Reached Label Talks Before Decision Date
D-PLEX100, PolyPid's only drug near the market, is an antibiotic that releases slowly at the site of bowel surgery to prevent infection. The FDA is running a faster review and plans to decide by November 28.
Chief executive Dikla Czaczkes Akselbrad called the decision “a defining moment for PolyPid”. The Israeli company said talks with the FDA on the wording of the label are under way, and every scheduled meeting is on track. Those steps move the review to its final stage, but the agency can still reject the drug or ask for more work.
What to watch: the FDA decision and the label text that comes with it. A broad label would let Azurity, PolyPid's US sales partner, start selling in early 2027 as planned.
Azurity Has Now Paid the Full $30 Million
Azurity will sell D-PLEX100, PolyPid's slow-release antibiotic for bowel surgery, in the US and Canada under a deal signed in July. The deal paid $15 million at signing and promised $15 million more once the FDA accepted the application.
Both payments have now arrived; the second landed just after September 30. PolyPid booked the full $30 million as deferred revenue, cash received for work it has not yet delivered. The deal also keeps the drug developer in manufacturing: it will make every unit and sell it to Azurity at “a pre-negotiated transfer price for each unit”, plus royalties.
What to watch: the transfer price, which PolyPid has not published, because it decides what each sale is worth to PolyPid beyond royalties.
PolyPid Filed in Europe and Regained Sales Rights
PolyPid wants to sell D-PLEX100, its slow-release antibiotic for bowel surgery, in Europe too. ADVANZ PHARMA had held those rights since 2022.
On September 14 PolyPid filed with the European Medicines Agency (EMA), the EU drug regulator, meeting its “previously communicated third quarter 2026 timeline”. The EMA has since accepted the file, and ADVANZ handed the rights back after both sides ended their deal.
This matters because the Israeli drug developer can now offer Europe to a new partner. So far it has only “active discussions with potential commercial partners”, and it expects an EMA decision in the second half of 2027.
What to watch: the name of a European partner and its upfront payment, which would bring cash before any approval in Europe.
🐻 Bear Case
Losses Rose Once a One-Off Gain Is Removed
PolyPid reported a smaller net loss of $5.8 million, against $7.5 million a year earlier. But that includes $2.5 million of other income from “the recognition of previously deferred revenue” after its old European deal ended. The gain brought in no cash.
Without the gain, the loss widened. PolyPid tied higher research spending to “ongoing NDA-related activities and continued commercial readiness preparation”, meaning work on its US approval filing and on launch plans.
- Net loss excluding the gain: $8.3 million by our math, up 11% from a year ago
- Research and development: $6.5 million, up 24%
- Total operating expenses: $8.5 million, up 14%
What to watch: operating expenses in the fourth-quarter results, the first full quarter after the FDA decision. A further rise would shorten the time PolyPid's cash lasts.
Cash Covers Under Four Quarters Without Approval Payments
PolyPid said its cash, “together with its expected proceeds from its commercialization agreement with Azurity, as well as future potential proceeds”, will fund operations into 2028. Azurity will sell D-PLEX100, PolyPid's slow-release antibiotic for bowel surgery, in the US.
The Israeli company ended September with $15.5 million in cash and deposits. Azurity's second payment, which arrived after the quarter, lifts that to about $30.5 million, by our math. By our math, the sum covers about 3.6 quarters at this quarter's pace of spending. Without new payments from approval or sales, it would run out before 2028.
This matters because PolyPid has funded itself by selling shares. Shares in issue reached 21.1 million, up 27% from a year ago, as investors used warrants, rights to buy shares at a set price. The milestone payments behind the 2028 plan have no published sizes or triggers.
What to watch: cash at December 31 and whether PolyPid names the payment due on approval. A sizable approval payment would carry the drug developer into 2028 without selling more shares.
Extra Hospital Payment Decision Comes After Launch
Medicare, the US health programme for older people, can grant hospitals “additional hospital reimbursement” for some new treatments through a scheme called NTAP. PolyPid has applied for D-PLEX100, its slow-release antibiotic for bowel surgery.
The Israeli drug developer expects a decision in August 2027. Azurity, its US sales partner, plans to launch in early 2027 if the FDA approves the drug. So hospitals will decide whether to stock the drug for months without knowing about the extra payment. This matters because PolyPid earns from Azurity's sales, so slow hospital uptake delays its income.
What to watch: how many hospitals add D-PLEX100 to their approved drug lists in the first months after launch. Quick listing would show hospitals buy it before Medicare settles the payment question.
Risks this quarter didn't answer
Four standing risks around D-PLEX100, PolyPid's slow-release antibiotic for bowel surgery, got no new figures or dates in the quarterly release.
- FDA inspection of the Israeli factory: no date given, though the decision is due by November 28
- Width of the label: talks have begun, but PolyPid gave no detail on which patients it covers
- Azurity milestones: still over $290 million with no sizes or triggers attached
- Factory and currency: no plan for a second plant, and no update on costs paid in Israeli shekels
What to watch: the FDA decision letter, because it will show both whether the factory cleared inspection in time and how wide the label is.
👓 Other Themes
PolyPid Added a Diabetic Foot Infection Drug Candidate
On October 28, PolyPid introduced PD01B, a drug candidate for diabetic foot infections. Chief executive Dikla Czaczkes Akselbrad called the disease “a serious condition where systemic antibiotics often fall short”. PD01B uses the technology behind D-PLEX100, its bowel-surgery antibiotic, to “deliver high-concentration doxycycline in the wound for weeks”. Its obesity project, PD03A, “continues in early preclinical development”. PolyPid expects first tests in people in the second half of 2027.
💲 Other KPIs
General and administrative costs, the expense of running the business outside research, fell 13% from a year ago. They have now dropped for two quarters, after rising in the quarters before, because non-cash charges for performance-based share options faded once those options vested. The saving offsets only a small part of the higher research bill.
Pre-launch inventory, product PolyPid makes ahead of approval, rose 15% in the quarter to $1.6 million. The stock sat still in the first quarter, then built up in the second and third, and stands 42% above December. It ties up cash before Azurity, the US partner, can buy any units.
Shareholders' equity, assets minus liabilities, fell to $3.9 million from $11.0 million in December. Losses outran money raised from share sales. The Azurity payments sit on the balance sheet as a liability, deferred revenue, until PolyPid earns them, so equity stays thin even though cash rose.
🔮 Guidance
Unchanged. The FDA still plans to rule on D-PLEX100, PolyPid's slow-release antibiotic for bowel surgery, by November 28. A faster review had already brought the date forward from the first quarter of 2027, the timing PolyPid gave after its first quarter.
Unchanged. Azurity, the US sales partner, still plans to launch D-PLEX100 in early 2027 if the FDA approves it. Azurity is building its US sales organisation now, so an approval in late November leaves it a few months to finish.
New. PolyPid plans to open talks with the FDA this quarter on using D-PLEX100 in a broader range of abdominal operations, beyond bowel surgery. A wider label would enlarge the market Azurity can sell into, but the drug developer has set no date for that approval.
New. PolyPid plans to file D-PLEX100 for approval in Canada in 2027. Canada sits inside the Azurity deal, so sales there would earn the same royalties as US sales.
New. PolyPid expects Medicare to decide in August 2027 on NTAP, an extra payment to hospitals that use D-PLEX100 on inpatients. That decision lands months after the planned early-2027 launch.
New. PolyPid expects the European Medicines Agency to decide on D-PLEX100 in the second half of 2027, now that the agency has accepted the application for review. The Israeli company holds the European rights again and is looking for a partner to sell the drug there.
New. PolyPid plans a pre-trial meeting with the FDA on PD01B, its diabetic foot infection candidate, and a first study in people, both in the second half of 2027. PD01B uses the same antibiotic, technology and factory as D-PLEX100, so it builds on work already done.
Unchanged. PolyPid still says cash, Azurity payments and “future potential proceeds” will fund operations into 2028. That is five quarters from September 30. By our math, cash plus the second Azurity payment covers about 3.6 quarters of current spending. The end date has moved out four times since 2024, each time after new money arrived.
❓ Key Questions
When will the FDA inspect the Israeli factory?
PolyPid makes D-PLEX100 at one site in Israel, and the FDA typically inspects a plant before approval. The drug developer has given no inspection date, although the decision falls on November 28.
What price will Azurity pay for each unit?
PolyPid earns a transfer price on every unit it makes for Azurity, plus royalties on sales. Without the price, readers cannot judge what each sale is worth to PolyPid.
How much of the $290 million comes with approval?
PolyPid can still earn over $290 million in milestone payments but has not split that sum by event. The approval payment decides whether cash lasts into 2028 without new share sales.
Over what period will the $30 million become revenue?
PolyPid booked the Azurity payments as deferred revenue. The schedule for turning them into revenue will shape reported results for years, even though the cash is already in hand.
Who will sell D-PLEX100 in Europe, and on what terms?
PolyPid regained the European rights and is in talks with possible partners. An upfront payment from a new partner would add cash before an EMA decision in the second half of 2027.